HYB timeline
Every HYB batch the index holds, newest manufacture date first, with the supplier's declared purity beside the median of the index's independent observations of the same lot.
| Lot | Compound | Manufactured | Quarter | Tests | Independent median | Spread (pp) | COA purity | Divergence (pp) | |
|---|---|---|---|---|---|---|---|---|---|
| HYB-2608-E3247 | CJC-1295 with DAC | 02 Aug 2026 | 2026-Q3 | 1 | 99.28 | n<2 | 99.24 | -0.04 | |
| HYB-2606-D3714 | MOTS-c | 18 Jun 2026 | 2026-Q3 | 1 | 99.93 | n<2 | 99.90 | -0.03 | |
| HYB-2604-D2514 | Retatrutide | 15 Apr 2026 | 2026-Q2 | 3 | 98.75 | 0.25 | 99.36 | +0.61 | |
| HYB-2603-U2989 | Epitalon | 16 Mar 2026 | 2026-Q2 | 1 | 99.46 | n<2 | 99.47 | +0.01 | |
| HYB-2601-N4037 | Larazotide acetate | 20 Jan 2026 | 2026-Q1 | 3 | 99.46 | 0.30 | 99.90 | +0.44 | |
| HYB-2512-P3881 | BPC-157 | 30 Dec 2025 | 2026-Q1 | 3 | 99.74 | 0.40 | 99.90 | +0.16 | |
| HYB-2512-W3093 | Tirzepatide | 12 Dec 2025 | 2026-Q2 | 10 | 98.96 | 0.86 | 98.75 | -0.21 | |
| HYB-2512-B3163 | Triptorelin | 02 Dec 2025 | 2026-Q1 | 1 | 99.42 | n<2 | 99.20 | -0.22 | |
| HYB-2512-B2435 | SS-31 (Elamipretide) | 01 Dec 2025 | 2026-Q2 | 2 | 99.79 | 0.13 | 99.90 | +0.11 | |
| HYB-2511-P3173 | KPV | 24 Nov 2025 | 2026-Q1 | 6 | 99.76 | 0.52 | 99.58 | -0.18 | |
| HYB-2511-F2307 | Semaglutide | 11 Nov 2025 | 2026-Q2 | 15 | 98.56 | 0.79 | 98.45 | -0.11 | |
| HYB-2511-R3760 | GHRP-6 | 03 Nov 2025 | 2025-Q4 | 4 | 99.90 | 0.22 | 99.90 | 0.00 | |
| HYB-2510-R3175 | Melanotan II | 31 Oct 2025 | 2026-Q1 | 5 | 99.93 | 0.16 | 99.90 | -0.03 | |
| HYB-2510-B3626 | CJC-1295 (no DAC) | 21 Oct 2025 | 2025-Q4 | 2 | 99.93 | 0.00 | 99.85 | -0.08 | |
| HYB-2510-H1978 | Semaglutide | 18 Oct 2025 | 2025-Q4 | 2 | 99.41 | 0.16 | 99.55 | +0.14 | |
| HYB-2510-J3326 | Melanotan II | 17 Oct 2025 | 2026-Q1 | 5 | 99.36 | 0.16 | 99.46 | +0.10 | |
| HYB-2510-J2260 | Enclomiphene citrate | 13 Oct 2025 | 2025-Q4 | 12 | 99.21 | 1.07 | 99.60 | +0.39 | |
| HYB-2509-W2321 | Retatrutide | 30 Sep 2025 | 2026-Q1 | 15 | 98.55 | 1.25 | 98.84 | +0.29 | |
| HYB-2509-K2822 | PT-141 (Bremelanotide) | 28 Sep 2025 | 2025-Q4 | 1 | 99.53 | n<2 | 99.54 | +0.01 | |
| HYB-2509-J2959 | Tirzepatide | 21 Sep 2025 | 2026-Q1 | 1 | 98.69 | n<2 | 99.07 | +0.38 | |
| HYB-2509-X3697 | MGF | 05 Sep 2025 | 2025-Q4 | 5 | 99.78 | 0.52 | 99.86 | +0.08 | |
| HYB-2508-R3378 | SS-31 (Elamipretide) | 30 Aug 2025 | 2026-Q1 | 1 | 99.93 | n<2 | 99.90 | -0.03 | SHARED BULK |
| HYB-2507-Y3341 | IGF-1 LR3 | 20 Jul 2025 | 2025-Q3 | 1 | 99.29 | n<2 | 99.62 | +0.33 | |
| HYB-2507-A2442 | Tirzepatide | 07 Jul 2025 | 2025-Q3 | 4 | 99.74 | 0.26 | 99.68 | -0.06 | |
| HYB-2505-M2715 | MK-677 (Ibutamoren mesylate) | 22 May 2025 | 2025-Q2 | 3 | 99.79 | 0.32 | 100.00 | +0.21 | |
| HYB-2504-X4157 | Survodutide | 26 Apr 2025 | 2025-Q3 | 7 | 98.59 | 1.73 | 98.33 | -0.26 | |
| HYB-2504-N3104 | CJC-1295 (no DAC) | 03 Apr 2025 | 2025-Q3 | 12 | 99.17 | 0.78 | 99.19 | +0.02 | |
| HYB-2503-D3751 | Ipamorelin | 04 Mar 2025 | 2025-Q3 | 7 | 99.93 | 0.27 | 99.90 | -0.03 | |
| HYB-2502-S3470 | L-Glutathione (reduced) | 28 Feb 2025 | 2025-Q2 | 6 | 99.51 | 0.72 | 99.87 | +0.36 | |
| HYB-2502-G4133 | BPC-157 | 25 Feb 2025 | 2025-Q3 | 12 | 99.87 | 0.44 | 99.90 | +0.03 | |
| HYB-2502-E3659 | Exenatide | 24 Feb 2025 | 2025-Q1 | 4 | 99.22 | 0.37 | 99.45 | +0.23 | |
| HYB-2502-R2041 | BPC-157 | 11 Feb 2025 | 2025-Q1 | 8 | 99.77 | 0.49 | 99.46 | -0.31 | |
| HYB-2501-T2146 | Dihexa | 09 Jan 2025 | 2025-Q2 | 1 | 99.75 | n<2 | 99.80 | +0.05 | |
| HYB-2501-R3096 | GHRP-2 | 08 Jan 2025 | 2025-Q1 | 6 | 99.66 | 0.46 | 99.37 | -0.29 | |
| HYB-2410-R4426 | TB-500 | 28 Oct 2024 | 2024-Q4 | 5 | 99.37 | 0.73 | 99.75 | +0.38 | |
| HYB-2410-J3413 | TB-500 | 27 Oct 2024 | 2025-Q1 | 6 | 99.83 | 0.29 | 99.76 | -0.07 | |
| HYB-2409-X1917 | BPC-157 | 14 Sep 2024 | 2024-Q4 | 8 | 99.15 | 0.67 | 99.12 | -0.03 | |
| HYB-2408-W2157 | Tirzepatide | 15 Aug 2024 | 2025-Q1 | 8 | 98.98 | 1.13 | 99.06 | +0.08 | |
| HYB-2408-N2987 | Enclomiphene citrate | 13 Aug 2024 | 2024-Q4 | 5 | 99.79 | 0.35 | 99.90 | +0.11 | |
| HYB-2408-V3296 | Tirzepatide | 11 Aug 2024 | 2024-Q3 | 1 | 98.50 | n<2 | 98.73 | +0.23 | |
| HYB-2408-R2871 | Tirzepatide | 06 Aug 2024 | 2025-Q1 | 3 | 97.75 | 0.61 | 98.10 | +0.35 | |
| HYB-2407-J2548 | Exenatide | 29 Jul 2024 | 2024-Q3 | 1 | 99.00 | n<2 | 98.97 | -0.03 | |
| HYB-2407-N3357 | GHRP-2 | 23 Jul 2024 | 2024-Q3 | 2 | 99.61 | 0.65 | 99.89 | +0.28 | |
| HYB-2407-V2291 | Semaglutide | 17 Jul 2024 | 2024-Q4 | 2 | 98.69 | 0.84 | 98.36 | -0.33 | |
| HYB-2407-N3223 | Hexarelin | 07 Jul 2024 | 2024-Q3 | 8 | 99.75 | 0.27 | 100.00 | +0.25 | |
| HYB-2407-W2450 | Retatrutide | 05 Jul 2024 | 2024-Q3 | 3 | 98.37 | 0.46 | 98.94 | +0.57 | |
| HYB-2405-C3486 | Selank | 10 May 2024 | 2024-Q2 | 11 | 99.70 | 0.51 | 99.90 | +0.20 | |
| HYB-2405-B2561 | CJC-1295 (no DAC) | 07 May 2024 | 2024-Q2 | 12 | 99.16 | 0.75 | 99.90 | +0.74 | |
| HYB-2403-B3157 | ARA-290 | 24 Mar 2024 | 2024-Q3 | 2 | 99.33 | 0.31 | 99.40 | +0.07 | |
| HYB-2403-C3843 | Humanin (HNG) | 02 Mar 2024 | 2024-Q2 | 10 | 99.62 | 0.45 | 99.48 | -0.14 |